Keywords: |
treatment outcome; genetics; histopathology; sorafenib; sunitinib; advanced cancer; antineoplastic agents; benzenesulfonates; pyridines; note; positron emission tomography; antineoplastic agent; adenocarcinoma; vasculotropin receptor; metastasis; progression free survival; protein kinase inhibitor; carcinoma, papillary; tumor markers, biological; editorial; practice guideline; pathology; tumor marker; protein kinase inhibitors; vandetanib; neoplasm metastasis; ras protein; thyroid neoplasms; external beam radiotherapy; papillary carcinoma; axitinib; motesanib; indoles; pyrroles; environmental factor; indole derivative; genetic code; thyroid papillary carcinoma; b raf kinase; thyroid tumor; adenocarcinoma, follicular; fluorodeoxyglucose; 5 (4 bromo 2 chloroanilino) 4 fluoro 1 methyl 1h benzimidazole 6 carbohydroxamic acid 2 hydroxyethyl ester; phosphotransferase inhibitor; pyrrole derivative; benzenesulfonic acid derivative; pyridine derivative; medullary carcinoma; carcinoma, medullary; plx 4032; thyroid medullary carcinoma
|